Cencora, Inc. (COR)
NYSE: COR · Real-Time Price · USD
312.53
+4.46 (1.45%)
At close: Sep 30, 2025, 4:00 PM EDT
309.43
-3.10 (-0.99%)
After-hours: Sep 30, 2025, 5:51 PM EDT
Cencora Market Cap
Cencora has a market cap or net worth of $60.59 billion as of September 30, 2025. Its market cap has increased by 29.39% in one year.
Market Cap
60.59B
Enterprise Value
68.28B
1-Year Change
29.39%
Ranking
Category
Stock Price
$312.53
Market Cap Chart
Since December 1, 1998, Cencora's market cap has increased from $1.54B to $60.59B, an increase of 3,841.50%. That is a compound annual growth rate of 14.67%.
Market Cap History
Date | Market Cap | % Change |
---|---|---|
Sep 29, 2025 | 59.73B | 37.54% |
Dec 31, 2024 | 43.43B | 5.35% |
Dec 29, 2023 | 41.22B | 20.95% |
Dec 30, 2022 | 34.08B | 23.22% |
Dec 31, 2021 | 27.66B | 38.52% |
Dec 31, 2020 | 19.97B | 14.05% |
Dec 31, 2019 | 17.51B | 11.03% |
Dec 31, 2018 | 15.77B | -21.26% |
Dec 29, 2017 | 20.02B | 16.36% |
Dec 30, 2016 | 17.21B | -19.30% |
Dec 31, 2015 | 21.33B | 8.16% |
Dec 31, 2014 | 19.72B | 21.91% |
Dec 31, 2013 | 16.17B | 59.07% |
Dec 31, 2012 | 10.17B | 5.83% |
Dec 30, 2011 | 9.61B | 1.90% |
Dec 31, 2010 | 9.43B | 25.55% |
Dec 31, 2009 | 7.51B | 34.82% |
Dec 31, 2008 | 5.57B | -26.08% |
Dec 31, 2007 | 7.54B | -12.74% |
Dec 29, 2006 | 8.64B | 0.04% |
Dec 30, 2005 | 8.63B | 39.95% |
Dec 31, 2004 | 6.17B | -2.03% |
Dec 31, 2003 | 6.30B | 8.40% |
Dec 31, 2002 | 5.81B | -11.90% |
Dec 31, 2001 | 6.59B | 149.72% |
View and export this data all the way back to 1998. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
Company | Market Cap |
---|---|
Eli Lilly and Company | 652.21B |
Johnson & Johnson | 437.40B |
AbbVie | 394.23B |
UnitedHealth Group | 312.62B |
Novo Nordisk | 245.50B |
Novartis AG | 240.62B |
Abbott Laboratories | 231.67B |
AstraZeneca | 231.02B |